Lindsay Fischer

“If you're an oncology nurse, you will have patients with immunotherapy–which is why we want to make sure that we are really familiar with these side effects.”

Belzutifan, a hypoxia-inducible factor inhibitor, has been approved for treatment of adults with cancers related to von Hippel-Lindau disease.

Although the use of CAR T-cell therapies are associated with potentially serious adverse events, the treatment provides patients whose disease has failed to respond to previous treatments with hope, according to Kelly Garvin, BSN, RN, OCN.

Teresa Knoop, MSN, RN, AOCN, says it is important for oncology nurses to understand the naming convention of biosimilars as it is an important aspect of anticipating adverse events.

Beth Sandy, MSN, CRNP, OCN, says that she would like to see 95% of eligible patients receive biomarker testing in the next 5 to 10 years.

Patients with metastatic castrate-resistant prostate cancer and PTEN-loss tumors experienced improved radiographical progression-free survival with ipatasertib plus abiraterone.

From orchestrating local infusion appointments to making lunch for a patient, Kathleen Lutz, RN, NP-BC WH, constantly strives to provide an excellent level of supportive care.

“[Drug adherence] seems like a problem we could potentially solve or, at least, make much better, and we are not really doing enough right now to do that.”

At 12 months, 97% patients treated with single infusions of cilta-cel had responded to the therapy.

The FDA has approved the first immunotherapy, pembrolizumab (Keytruda), to treat patients with high-risk early-stage triple-negative breast cancer.

The International Association for the Study of Lung Cancer (IASLC) has published an updated consensus on the use of liquid biopsy in screening non-small cell lung cancer (NSCLC).

The FDA has granted a breakthrough therapy designation for venetoclax following interim results from the ongoing M15-531 trial.

Lisa Cusaac never planned on being an oncology nurse. However, 25 years later she has spent her entire career providing care for patients with cancer and being an Oncology Nurse Champion.

The combination of ficlatuzumab and chemotherapy demonstrated some promising results in a small group of patients with relapsed/refractory acute myeloid leukemia.

A trial evaluating melflufen in myeloma met its primary end point of progression free survival in the phase 3 OCEAN trial; however, overall survival was in favor of pomalidomide.

The FDA has offered support and encouragement for the development of paclitaxel plus encequidar.

The Food and Drug Administration has approved pembrolizumab for the treatment of patients with a locally advanced form of skin cancer.

Out of 30 patients, 16 demonstrated significant pathological responses and 8 achieved a complete pathological response.

A retrospective cohort study found that convalescent plasma treatment resulted in a meaningful improvement in the 30-day mortality rate for patients with hematologic cancer and COVID-19.

ASCO updated its guidelines following a presentation of the OlympiA trial presented at its 2021 Annual Meeting.

A presentation at the 2021 American Society of Clinical Oncology Meeting demonstrated that the use of electronic patient-reported outcomes in community oncology centers improved symptom-management.

Nearly half of patients with gynecologic cancer reported financial distress, or financial toxicity, new study says.

“Looking at how the movement toward videoconferencing visits during the COVID-19 pandemic affects the nurse-patient relationship and the capacity to maintain high quality, supportive cancer care is essential…”

A Texas study revealed that the implementation of electronic patient management solutions resulted in reduced call back times for symptom-related calls as well as reduced hospitalizations.

The FDA granted a priority review for a Biologics License Application (BLA) to bastilimab for the treatment of recurrent or metastatic cervical cancer.